22. phytotherapy for carcinoma of prostate yip andrew
Rapid Measurement of Lung Cancer Biomarkers
1. PROTEOMICS
Rapid Measurement of Lung
Cancer Biomarkers
Ambermarie Dawdy
August 01, 2016
Jin H. Park, Biochem J., 2012,448(Pt 3): 417-423
2. Why Should we Study Lung Cancer?
Rebecca L. Siegel, CA CANCER J CLIN 2016,66, 11-18
Estimated New Cases
Prostate 21%
Lung & Bronchus 14%
Colon & Rectum 8%
Urinary Bladder 7%
Melanoma 6%
Lymphoma 5%
Kidney & Renal 5%
Oral & Pharynx 4%
Leukemia 4%
Liver & Bile Duct 3%
Lung & Bronchus 27%
Prostate 8%
Colon & Rectum 8%
Pancreas 7%
Liver & Bile Duct 3%
Leukemia 4%
Esophagus 4%
Urinary Bladder 4%
Lymphoma 4%
Brain & Nervous 3%
Breast
Lung & Bronchus
Colon & Rectum
Uterine corpus
Thyroid
Lymphoma
Melanoma
Leukemia
Pancreas
Kidney & Renal
Lung & Bronchus
Breast
Colon & Rectum
Pancreas
Ovary
Uterine corpus
Leukemia
Liver & Bile Duct
Lymphoma
Brain & Nervous
Estimated Deaths
29%
13%
8%
7%
6%
4%
3%
3%
3%
3%
26%
14%
8%
7%
5%
4%
4%
3%
3%
2%
*17,369 Cases of estimated new cases in Florida and 11,960 estimated deaths from lung cancer
3. What are Biomarkers?
• Measurable substances in
organisms whose presence is
indicative of a biological
occurrence such as
disease/infection
• Tissue microarray is used to
remove sections of tumor
tissue and clinical biopsies
• Reduces the time it takes to
process tissue microarrays
from 3 hours a sample to 12
minutes a sample
Mascaux C, Clin Cancer Res, 2011,17, 7801
7. SUMMARY
● Lung Cancer has Poor Patient Outcomes
● Improved assessment of biomarkers can help
the patient
● Goal: Develop and implement new methods for
biomarker detection
8. Acknowledgments
Funding: Frank E. Duckwall Foundation, Saunders Foundation, Moffitt
Cancer Center
Koomen Lab
John Koomen, PhD
Melissa Martinez
Omar Chavez-Chiang, MD
Proteomics Core
Bin Fang, PhD
Lancia Darville, PhD
Victoria Izumi
Kiah Bowers
SPARK
Doug Cress, PhD
Evelyn Rivera-Miranda
Moffitt Cancer Center
Moffitt Foundation
